nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—SLC22A1—Cytarabine—lymphatic system cancer	0.205	0.269	CbGbCtD
Midazolam—CYP3A5—Teniposide—lymphatic system cancer	0.0953	0.125	CbGbCtD
Midazolam—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0857	0.112	CbGbCtD
Midazolam—CYP3A7—Vincristine—lymphatic system cancer	0.0611	0.08	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0611	0.08	CbGbCtD
Midazolam—CYP3A5—Vincristine—lymphatic system cancer	0.0458	0.06	CbGbCtD
Midazolam—ABCB1—Mitoxantrone—lymphatic system cancer	0.0434	0.0567	CbGbCtD
Midazolam—CYP3A4—Cytarabine—lymphatic system cancer	0.0377	0.0493	CbGbCtD
Midazolam—CYP3A4—Teniposide—lymphatic system cancer	0.0371	0.0486	CbGbCtD
Midazolam—ABCB1—Vincristine—lymphatic system cancer	0.0298	0.039	CbGbCtD
Midazolam—CYP3A4—Mitoxantrone—lymphatic system cancer	0.026	0.034	CbGbCtD
Midazolam—ABCB1—Methotrexate—lymphatic system cancer	0.0181	0.0236	CbGbCtD
Midazolam—CYP3A4—Vincristine—lymphatic system cancer	0.0179	0.0234	CbGbCtD
Midazolam—Hypoxia—Fludarabine—lymphatic system cancer	0.00414	0.0176	CcSEcCtD
Midazolam—Digestion impaired—Fludarabine—lymphatic system cancer	0.00394	0.0167	CcSEcCtD
Midazolam—Local reaction—Bleomycin—lymphatic system cancer	0.00348	0.0148	CcSEcCtD
Midazolam—Obstructive airways disorder—Methotrexate—lymphatic system cancer	0.00344	0.0146	CcSEcCtD
Midazolam—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.00341	0.0145	CcSEcCtD
Midazolam—Local reaction—Mitoxantrone—lymphatic system cancer	0.00283	0.012	CcSEcCtD
Midazolam—Respiratory failure—Fludarabine—lymphatic system cancer	0.00268	0.0114	CcSEcCtD
Midazolam—Phlebitis—Teniposide—lymphatic system cancer	0.00252	0.0107	CcSEcCtD
Midazolam—Thrombosis—Carmustine—lymphatic system cancer	0.00238	0.0101	CcSEcCtD
Midazolam—Depression—Mechlorethamine—lymphatic system cancer	0.00227	0.00962	CcSEcCtD
Midazolam—Nystagmus—Vincristine—lymphatic system cancer	0.00225	0.00955	CcSEcCtD
Midazolam—Skin necrosis—Methotrexate—lymphatic system cancer	0.00223	0.00948	CcSEcCtD
Midazolam—Phlebitis—Fludarabine—lymphatic system cancer	0.00222	0.00941	CcSEcCtD
Midazolam—Tenderness—Bleomycin—lymphatic system cancer	0.00221	0.00939	CcSEcCtD
Midazolam—Sleep disorder—Fludarabine—lymphatic system cancer	0.00221	0.00937	CcSEcCtD
Midazolam—Aggression—Bleomycin—lymphatic system cancer	0.0022	0.00932	CcSEcCtD
Midazolam—Injection site pain—Carmustine—lymphatic system cancer	0.00206	0.00876	CcSEcCtD
Midazolam—Visual disturbance—Fludarabine—lymphatic system cancer	0.00202	0.00856	CcSEcCtD
Midazolam—Cardiac failure—Fludarabine—lymphatic system cancer	0.00196	0.00831	CcSEcCtD
Midazolam—Wheezing—Bleomycin—lymphatic system cancer	0.00187	0.00795	CcSEcCtD
Midazolam—Bronchospasm—Teniposide—lymphatic system cancer	0.00185	0.00784	CcSEcCtD
Midazolam—Skin exfoliation—Bleomycin—lymphatic system cancer	0.00184	0.00782	CcSEcCtD
Midazolam—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00164	0.00697	CcSEcCtD
Midazolam—Respiratory failure—Vincristine—lymphatic system cancer	0.00164	0.00695	CcSEcCtD
Midazolam—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00163	0.0069	CcSEcCtD
Midazolam—Phlebitis—Bleomycin—lymphatic system cancer	0.00163	0.0069	CcSEcCtD
Midazolam—Skin exfoliation—Carmustine—lymphatic system cancer	0.00161	0.00683	CcSEcCtD
Midazolam—Vertigo—Mechlorethamine—lymphatic system cancer	0.00159	0.00677	CcSEcCtD
Midazolam—Disorientation—Bleomycin—lymphatic system cancer	0.00157	0.00665	CcSEcCtD
Midazolam—Injury—Bleomycin—lymphatic system cancer	0.00152	0.00647	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0015	0.00637	CcSEcCtD
Midazolam—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00145	0.00615	CcSEcCtD
Midazolam—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00144	0.00613	CcSEcCtD
Midazolam—Phlebitis—Carmustine—lymphatic system cancer	0.00142	0.00602	CcSEcCtD
Midazolam—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00141	0.00599	CcSEcCtD
Midazolam—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00141	0.00597	CcSEcCtD
Midazolam—Swelling—Carmustine—lymphatic system cancer	0.00139	0.00588	CcSEcCtD
Midazolam—Chills—Teniposide—lymphatic system cancer	0.00135	0.00573	CcSEcCtD
Midazolam—Multiple fractures—Methotrexate—lymphatic system cancer	0.00134	0.0057	CcSEcCtD
Midazolam—Fracture—Methotrexate—lymphatic system cancer	0.00134	0.0057	CcSEcCtD
Midazolam—Injury—Carmustine—lymphatic system cancer	0.00133	0.00565	CcSEcCtD
Midazolam—Phlebitis—Mitoxantrone—lymphatic system cancer	0.00132	0.0056	CcSEcCtD
Midazolam—Swelling—Mitoxantrone—lymphatic system cancer	0.00129	0.00547	CcSEcCtD
Midazolam—Visual impairment—Fludarabine—lymphatic system cancer	0.00127	0.00541	CcSEcCtD
Midazolam—Hypoxia—Methotrexate—lymphatic system cancer	0.00123	0.00521	CcSEcCtD
Midazolam—Diplopia—Carmustine—lymphatic system cancer	0.00122	0.00519	CcSEcCtD
Midazolam—Agitation—Teniposide—lymphatic system cancer	0.0012	0.00511	CcSEcCtD
Midazolam—Bronchospasm—Bleomycin—lymphatic system cancer	0.00119	0.00505	CcSEcCtD
Midazolam—Chills—Fludarabine—lymphatic system cancer	0.00119	0.00503	CcSEcCtD
Midazolam—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00117	0.00498	CcSEcCtD
Midazolam—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00116	0.00494	CcSEcCtD
Midazolam—Ataxia—Carmustine—lymphatic system cancer	0.00115	0.00488	CcSEcCtD
Midazolam—Cardiac arrest—Vincristine—lymphatic system cancer	0.00111	0.00471	CcSEcCtD
Midazolam—Ataxia—Vincristine—lymphatic system cancer	0.0011	0.00466	CcSEcCtD
Midazolam—Muscular weakness—Carmustine—lymphatic system cancer	0.00108	0.00458	CcSEcCtD
Midazolam—Confusional state—Teniposide—lymphatic system cancer	0.00108	0.00457	CcSEcCtD
Midazolam—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00107	0.00453	CcSEcCtD
Midazolam—Agitation—Fludarabine—lymphatic system cancer	0.00106	0.00449	CcSEcCtD
Midazolam—Tachycardia—Teniposide—lymphatic system cancer	0.00104	0.00443	CcSEcCtD
Midazolam—Muscular weakness—Vincristine—lymphatic system cancer	0.00103	0.00437	CcSEcCtD
Midazolam—Pruritus—Mechlorethamine—lymphatic system cancer	0.00103	0.00435	CcSEcCtD
Midazolam—Cough—Fludarabine—lymphatic system cancer	0.001	0.00426	CcSEcCtD
Midazolam—Hypotension—Teniposide—lymphatic system cancer	0.000998	0.00424	CcSEcCtD
Midazolam—Dyspnoea—Teniposide—lymphatic system cancer	0.000952	0.00404	CcSEcCtD
Midazolam—Confusional state—Fludarabine—lymphatic system cancer	0.000947	0.00402	CcSEcCtD
Midazolam—Depression—Carmustine—lymphatic system cancer	0.000939	0.00399	CcSEcCtD
Midazolam—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000939	0.00399	CcSEcCtD
Midazolam—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000923	0.00392	CcSEcCtD
Midazolam—Vomiting—Mechlorethamine—lymphatic system cancer	0.000921	0.00391	CcSEcCtD
Midazolam—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000921	0.00391	CcSEcCtD
Midazolam—Apnoea—Methotrexate—lymphatic system cancer	0.00092	0.00391	CcSEcCtD
Midazolam—Rash—Mechlorethamine—lymphatic system cancer	0.000914	0.00388	CcSEcCtD
Midazolam—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000913	0.00387	CcSEcCtD
Midazolam—Depression—Vincristine—lymphatic system cancer	0.000897	0.00381	CcSEcCtD
Midazolam—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000881	0.00374	CcSEcCtD
Midazolam—Feeling abnormal—Teniposide—lymphatic system cancer	0.00088	0.00374	CcSEcCtD
Midazolam—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000876	0.00372	CcSEcCtD
Midazolam—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.000869	0.00369	CcSEcCtD
Midazolam—Chills—Bleomycin—lymphatic system cancer	0.000869	0.00369	CcSEcCtD
Midazolam—Nausea—Mechlorethamine—lymphatic system cancer	0.000861	0.00365	CcSEcCtD
Midazolam—Urticaria—Teniposide—lymphatic system cancer	0.000849	0.0036	CcSEcCtD
Midazolam—Erythema—Bleomycin—lymphatic system cancer	0.000843	0.00358	CcSEcCtD
Midazolam—Paraesthesia—Fludarabine—lymphatic system cancer	0.000843	0.00358	CcSEcCtD
Midazolam—Hallucination—Carmustine—lymphatic system cancer	0.000841	0.00357	CcSEcCtD
Midazolam—Dyspnoea—Fludarabine—lymphatic system cancer	0.000837	0.00355	CcSEcCtD
Midazolam—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000831	0.00353	CcSEcCtD
Midazolam—Dyspepsia—Fludarabine—lymphatic system cancer	0.000826	0.00351	CcSEcCtD
Midazolam—Dysarthria—Methotrexate—lymphatic system cancer	0.000825	0.0035	CcSEcCtD
Midazolam—Visual impairment—Carmustine—lymphatic system cancer	0.000815	0.00346	CcSEcCtD
Midazolam—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00081	0.00344	CcSEcCtD
Midazolam—Fatigue—Fludarabine—lymphatic system cancer	0.000809	0.00344	CcSEcCtD
Midazolam—Hallucination—Vincristine—lymphatic system cancer	0.000803	0.00341	CcSEcCtD
Midazolam—Pain—Fludarabine—lymphatic system cancer	0.000803	0.00341	CcSEcCtD
Midazolam—Constipation—Fludarabine—lymphatic system cancer	0.000803	0.00341	CcSEcCtD
Midazolam—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0008	0.0034	CcSEcCtD
Midazolam—Respiratory failure—Methotrexate—lymphatic system cancer	0.000794	0.00337	CcSEcCtD
Midazolam—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000793	0.00337	CcSEcCtD
Midazolam—Eye disorder—Carmustine—lymphatic system cancer	0.00079	0.00336	CcSEcCtD
Midazolam—Hypersensitivity—Teniposide—lymphatic system cancer	0.000787	0.00334	CcSEcCtD
Midazolam—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000774	0.00328	CcSEcCtD
Midazolam—Asthenia—Teniposide—lymphatic system cancer	0.000766	0.00325	CcSEcCtD
Midazolam—Pruritus—Teniposide—lymphatic system cancer	0.000756	0.00321	CcSEcCtD
Midazolam—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000753	0.0032	CcSEcCtD
Midazolam—Cardiac disorder—Vincristine—lymphatic system cancer	0.000749	0.00318	CcSEcCtD
Midazolam—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000745	0.00316	CcSEcCtD
Midazolam—Mental disorder—Carmustine—lymphatic system cancer	0.000741	0.00315	CcSEcCtD
Midazolam—Erythema—Carmustine—lymphatic system cancer	0.000736	0.00313	CcSEcCtD
Midazolam—Cough—Bleomycin—lymphatic system cancer	0.000736	0.00312	CcSEcCtD
Midazolam—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000728	0.00309	CcSEcCtD
Midazolam—Mental disorder—Vincristine—lymphatic system cancer	0.000707	0.003	CcSEcCtD
Midazolam—Chills—Mitoxantrone—lymphatic system cancer	0.000705	0.00299	CcSEcCtD
Midazolam—Confusional state—Bleomycin—lymphatic system cancer	0.000694	0.00295	CcSEcCtD
Midazolam—Vision blurred—Carmustine—lymphatic system cancer	0.000694	0.00295	CcSEcCtD
Midazolam—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000692	0.00294	CcSEcCtD
Midazolam—Tremor—Carmustine—lymphatic system cancer	0.00069	0.00293	CcSEcCtD
Midazolam—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000688	0.00292	CcSEcCtD
Midazolam—Erythema—Mitoxantrone—lymphatic system cancer	0.000684	0.00291	CcSEcCtD
Midazolam—Vomiting—Teniposide—lymphatic system cancer	0.000679	0.00288	CcSEcCtD
Midazolam—Agitation—Carmustine—lymphatic system cancer	0.000677	0.00287	CcSEcCtD
Midazolam—Asthenia—Fludarabine—lymphatic system cancer	0.000674	0.00286	CcSEcCtD
Midazolam—Rash—Teniposide—lymphatic system cancer	0.000673	0.00286	CcSEcCtD
Midazolam—Dermatitis—Teniposide—lymphatic system cancer	0.000673	0.00286	CcSEcCtD
Midazolam—Headache—Teniposide—lymphatic system cancer	0.000669	0.00284	CcSEcCtD
Midazolam—Pruritus—Fludarabine—lymphatic system cancer	0.000664	0.00282	CcSEcCtD
Midazolam—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000654	0.00278	CcSEcCtD
Midazolam—Agitation—Vincristine—lymphatic system cancer	0.000646	0.00274	CcSEcCtD
Midazolam—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000645	0.00274	CcSEcCtD
Midazolam—Hypotension—Bleomycin—lymphatic system cancer	0.000643	0.00273	CcSEcCtD
Midazolam—Nausea—Teniposide—lymphatic system cancer	0.000634	0.00269	CcSEcCtD
Midazolam—Vertigo—Vincristine—lymphatic system cancer	0.000631	0.00268	CcSEcCtD
Midazolam—Anxiety—Carmustine—lymphatic system cancer	0.000625	0.00265	CcSEcCtD
Midazolam—Paraesthesia—Bleomycin—lymphatic system cancer	0.000618	0.00262	CcSEcCtD
Midazolam—Dyspnoea—Bleomycin—lymphatic system cancer	0.000614	0.00261	CcSEcCtD
Midazolam—Confusional state—Carmustine—lymphatic system cancer	0.000606	0.00257	CcSEcCtD
Midazolam—Visual disturbance—Methotrexate—lymphatic system cancer	0.000598	0.00254	CcSEcCtD
Midazolam—Cough—Mitoxantrone—lymphatic system cancer	0.000597	0.00254	CcSEcCtD
Midazolam—Vomiting—Fludarabine—lymphatic system cancer	0.000597	0.00253	CcSEcCtD
Midazolam—Rash—Fludarabine—lymphatic system cancer	0.000592	0.00251	CcSEcCtD
Midazolam—Dermatitis—Fludarabine—lymphatic system cancer	0.000591	0.00251	CcSEcCtD
Midazolam—Pain—Bleomycin—lymphatic system cancer	0.000589	0.0025	CcSEcCtD
Midazolam—Headache—Fludarabine—lymphatic system cancer	0.000588	0.0025	CcSEcCtD
Midazolam—Tachycardia—Carmustine—lymphatic system cancer	0.000586	0.00249	CcSEcCtD
Midazolam—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000585	0.00248	CcSEcCtD
Midazolam—Anxiety—Mitoxantrone—lymphatic system cancer	0.000581	0.00246	CcSEcCtD
Midazolam—Lethargy—Methotrexate—lymphatic system cancer	0.000578	0.00245	CcSEcCtD
Midazolam—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000574	0.00243	CcSEcCtD
Midazolam—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000567	0.00241	CcSEcCtD
Midazolam—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000566	0.0024	CcSEcCtD
Midazolam—Confusional state—Mitoxantrone—lymphatic system cancer	0.000563	0.00239	CcSEcCtD
Midazolam—Nervous system disorder—Vincristine—lymphatic system cancer	0.000562	0.00239	CcSEcCtD
Midazolam—Hypotension—Carmustine—lymphatic system cancer	0.000561	0.00238	CcSEcCtD
Midazolam—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000559	0.00237	CcSEcCtD
Midazolam—Nausea—Fludarabine—lymphatic system cancer	0.000558	0.00237	CcSEcCtD
Midazolam—Shock—Mitoxantrone—lymphatic system cancer	0.00055	0.00233	CcSEcCtD
Midazolam—Urticaria—Bleomycin—lymphatic system cancer	0.000547	0.00232	CcSEcCtD
Midazolam—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000545	0.00231	CcSEcCtD
Midazolam—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000543	0.0023	CcSEcCtD
Midazolam—Irritability—Methotrexate—lymphatic system cancer	0.00054	0.00229	CcSEcCtD
Midazolam—Paraesthesia—Carmustine—lymphatic system cancer	0.00054	0.00229	CcSEcCtD
Midazolam—Mood swings—Methotrexate—lymphatic system cancer	0.000536	0.00228	CcSEcCtD
Midazolam—Hypotension—Vincristine—lymphatic system cancer	0.000536	0.00228	CcSEcCtD
Midazolam—Dyspnoea—Carmustine—lymphatic system cancer	0.000536	0.00227	CcSEcCtD
Midazolam—Somnolence—Carmustine—lymphatic system cancer	0.000534	0.00227	CcSEcCtD
Midazolam—Ataxia—Methotrexate—lymphatic system cancer	0.000532	0.00226	CcSEcCtD
Midazolam—Hypotension—Mitoxantrone—lymphatic system cancer	0.000522	0.00222	CcSEcCtD
Midazolam—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000519	0.0022	CcSEcCtD
Midazolam—Paraesthesia—Vincristine—lymphatic system cancer	0.000515	0.00219	CcSEcCtD
Midazolam—Pain—Carmustine—lymphatic system cancer	0.000514	0.00218	CcSEcCtD
Midazolam—Constipation—Carmustine—lymphatic system cancer	0.000514	0.00218	CcSEcCtD
Midazolam—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000507	0.00215	CcSEcCtD
Midazolam—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000502	0.00213	CcSEcCtD
Midazolam—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000498	0.00211	CcSEcCtD
Midazolam—Somnolence—Mitoxantrone—lymphatic system cancer	0.000497	0.00211	CcSEcCtD
Midazolam—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000495	0.0021	CcSEcCtD
Midazolam—Feeling abnormal—Carmustine—lymphatic system cancer	0.000495	0.0021	CcSEcCtD
Midazolam—Fatigue—Vincristine—lymphatic system cancer	0.000494	0.0021	CcSEcCtD
Midazolam—Asthenia—Bleomycin—lymphatic system cancer	0.000494	0.0021	CcSEcCtD
Midazolam—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000492	0.00209	CcSEcCtD
Midazolam—Constipation—Vincristine—lymphatic system cancer	0.00049	0.00208	CcSEcCtD
Midazolam—Pain—Vincristine—lymphatic system cancer	0.00049	0.00208	CcSEcCtD
Midazolam—Pruritus—Bleomycin—lymphatic system cancer	0.000487	0.00207	CcSEcCtD
Midazolam—Fatigue—Mitoxantrone—lymphatic system cancer	0.000482	0.00204	CcSEcCtD
Midazolam—Pain—Mitoxantrone—lymphatic system cancer	0.000478	0.00203	CcSEcCtD
Midazolam—Constipation—Mitoxantrone—lymphatic system cancer	0.000478	0.00203	CcSEcCtD
Midazolam—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00046	0.00195	CcSEcCtD
Midazolam—Urticaria—Mitoxantrone—lymphatic system cancer	0.000444	0.00188	CcSEcCtD
Midazolam—Hypersensitivity—Carmustine—lymphatic system cancer	0.000443	0.00188	CcSEcCtD
Midazolam—Vomiting—Bleomycin—lymphatic system cancer	0.000438	0.00186	CcSEcCtD
Midazolam—Drowsiness—Methotrexate—lymphatic system cancer	0.000436	0.00185	CcSEcCtD
Midazolam—Depression—Methotrexate—lymphatic system cancer	0.000435	0.00185	CcSEcCtD
Midazolam—Rash—Bleomycin—lymphatic system cancer	0.000434	0.00184	CcSEcCtD
Midazolam—Dermatitis—Bleomycin—lymphatic system cancer	0.000434	0.00184	CcSEcCtD
Midazolam—Asthenia—Carmustine—lymphatic system cancer	0.000431	0.00183	CcSEcCtD
Midazolam—Hypersensitivity—Vincristine—lymphatic system cancer	0.000423	0.00179	CcSEcCtD
Midazolam—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000412	0.00175	CcSEcCtD
Midazolam—Asthenia—Vincristine—lymphatic system cancer	0.000412	0.00175	CcSEcCtD
Midazolam—Nausea—Bleomycin—lymphatic system cancer	0.000409	0.00174	CcSEcCtD
Midazolam—Asthenia—Mitoxantrone—lymphatic system cancer	0.000401	0.0017	CcSEcCtD
Midazolam—Dizziness—Carmustine—lymphatic system cancer	0.000397	0.00169	CcSEcCtD
Midazolam—Vomiting—Carmustine—lymphatic system cancer	0.000382	0.00162	CcSEcCtD
Midazolam—Dizziness—Vincristine—lymphatic system cancer	0.000379	0.00161	CcSEcCtD
Midazolam—Rash—Carmustine—lymphatic system cancer	0.000379	0.00161	CcSEcCtD
Midazolam—Dermatitis—Carmustine—lymphatic system cancer	0.000378	0.00161	CcSEcCtD
Midazolam—Visual impairment—Methotrexate—lymphatic system cancer	0.000377	0.0016	CcSEcCtD
Midazolam—Headache—Carmustine—lymphatic system cancer	0.000376	0.0016	CcSEcCtD
Midazolam—Eye disorder—Methotrexate—lymphatic system cancer	0.000366	0.00155	CcSEcCtD
Midazolam—Vomiting—Vincristine—lymphatic system cancer	0.000365	0.00155	CcSEcCtD
Midazolam—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000364	0.00154	CcSEcCtD
Midazolam—Rash—Vincristine—lymphatic system cancer	0.000362	0.00154	CcSEcCtD
Midazolam—Dermatitis—Vincristine—lymphatic system cancer	0.000361	0.00153	CcSEcCtD
Midazolam—Headache—Vincristine—lymphatic system cancer	0.000359	0.00153	CcSEcCtD
Midazolam—Nausea—Carmustine—lymphatic system cancer	0.000357	0.00152	CcSEcCtD
Midazolam—Vomiting—Mitoxantrone—lymphatic system cancer	0.000355	0.00151	CcSEcCtD
Midazolam—Immune system disorder—Methotrexate—lymphatic system cancer	0.000354	0.0015	CcSEcCtD
Midazolam—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000353	0.0015	CcSEcCtD
Midazolam—Rash—Mitoxantrone—lymphatic system cancer	0.000352	0.0015	CcSEcCtD
Midazolam—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000352	0.00149	CcSEcCtD
Midazolam—Chills—Methotrexate—lymphatic system cancer	0.000351	0.00149	CcSEcCtD
Midazolam—Headache—Mitoxantrone—lymphatic system cancer	0.00035	0.00149	CcSEcCtD
Midazolam—Mental disorder—Methotrexate—lymphatic system cancer	0.000343	0.00146	CcSEcCtD
Midazolam—Erythema—Methotrexate—lymphatic system cancer	0.000341	0.00145	CcSEcCtD
Midazolam—Nausea—Vincristine—lymphatic system cancer	0.000341	0.00145	CcSEcCtD
Midazolam—Nausea—Mitoxantrone—lymphatic system cancer	0.000332	0.00141	CcSEcCtD
Midazolam—Vision blurred—Methotrexate—lymphatic system cancer	0.000321	0.00136	CcSEcCtD
Midazolam—Vertigo—Methotrexate—lymphatic system cancer	0.000306	0.0013	CcSEcCtD
Midazolam—Cough—Methotrexate—lymphatic system cancer	0.000298	0.00126	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000288	0.00122	CcSEcCtD
Midazolam—Confusional state—Methotrexate—lymphatic system cancer	0.000281	0.00119	CcSEcCtD
Midazolam—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000278	0.00118	CcSEcCtD
Midazolam—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000273	0.00116	CcSEcCtD
Midazolam—Skin disorder—Methotrexate—lymphatic system cancer	0.00027	0.00115	CcSEcCtD
Midazolam—Hypotension—Methotrexate—lymphatic system cancer	0.00026	0.0011	CcSEcCtD
Midazolam—Paraesthesia—Methotrexate—lymphatic system cancer	0.00025	0.00106	CcSEcCtD
Midazolam—Dyspnoea—Methotrexate—lymphatic system cancer	0.000248	0.00105	CcSEcCtD
Midazolam—Somnolence—Methotrexate—lymphatic system cancer	0.000247	0.00105	CcSEcCtD
Midazolam—Dyspepsia—Methotrexate—lymphatic system cancer	0.000245	0.00104	CcSEcCtD
Midazolam—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00024	0.00102	CcSEcCtD
Midazolam—Fatigue—Methotrexate—lymphatic system cancer	0.00024	0.00102	CcSEcCtD
Midazolam—Pain—Methotrexate—lymphatic system cancer	0.000238	0.00101	CcSEcCtD
Midazolam—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000229	0.000974	CcSEcCtD
Midazolam—Urticaria—Methotrexate—lymphatic system cancer	0.000221	0.000939	CcSEcCtD
Midazolam—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000205	0.00087	CcSEcCtD
Midazolam—Asthenia—Methotrexate—lymphatic system cancer	0.0002	0.000848	CcSEcCtD
Midazolam—Pruritus—Methotrexate—lymphatic system cancer	0.000197	0.000836	CcSEcCtD
Midazolam—Dizziness—Methotrexate—lymphatic system cancer	0.000184	0.000781	CcSEcCtD
Midazolam—Vomiting—Methotrexate—lymphatic system cancer	0.000177	0.000751	CcSEcCtD
Midazolam—Rash—Methotrexate—lymphatic system cancer	0.000175	0.000745	CcSEcCtD
Midazolam—Dermatitis—Methotrexate—lymphatic system cancer	0.000175	0.000744	CcSEcCtD
Midazolam—Headache—Methotrexate—lymphatic system cancer	0.000174	0.00074	CcSEcCtD
Midazolam—Nausea—Methotrexate—lymphatic system cancer	0.000165	0.000702	CcSEcCtD
